相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2009)
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
M. A. Nauck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Postmenopausal hormone therapy for disease prevention: Have we learned any lessons from the past?
J. E. Rossouw
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
Ronald Christopher et al.
CLINICAL THERAPEUTICS (2008)
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptino: A randomized, double-mind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
Paul Covington et al.
CLINICAL THERAPEUTICS (2008)
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control A randomized, double-blind, placebo-controlled study
Ralph A. DeFronzo et al.
DIABETES CARE (2008)
Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys
Bumsup Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance
Kirsten Vollmer et al.
DIABETES (2008)
AMH (Australian Medicines Handbook, 2007 Edition)
S E Tett
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
Jun Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?
A. J. Scheen
DIABETES & METABOLISM (2007)
Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives
M. Virally et al.
DIABETES & METABOLISM (2007)
Pathophysiology of type 2 diabetes: Rationale for different oral antidiabetic treatment strategies
F Giorgino et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2005)
Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus
DT Enrich et al.
PHARMACOTHERAPY (2005)
Incretins, insulin secretion and Type 2 diabetes mellitus
T Vilsboll et al.
DIABETOLOGIA (2004)
Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus
JJ Holst et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
J Buteau et al.
DIABETOLOGIA (2004)
Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030
S Wild et al.
DIABETES CARE (2004)
分享论文
